FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing

Approved proteasome inhibitors have advanced the treatment of multiple myeloma but are associated with serious toxicities, poor pharmacokinetics, and most with the inconvenience of intravenous administration. We therefore sought to identify novel orally bioavailable proteasome inhibitors with a cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Z, Dove, P, Wang, X, Shamas-Din, A, Li, Z, Nachman, A, Oh, Y J, Hurren, R, Ruschak, A, Climie, S, Press, B, Griffin, C, Undzys, E, Aman, A, Al-awar, R, Kay, L E, O'Neill, D, Trudel, S, Slassi, M, Schimmer, A D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650734/
https://www.ncbi.nlm.nih.gov/pubmed/26158521
http://dx.doi.org/10.1038/cddis.2015.187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650734/
https://www.ncbi.nlm.nih.gov/pubmed/26158521
http://dx.doi.org/10.1038/cddis.2015.187

Ejemplares similares